Quick answer
Kenji Watanabe is a APAC Pharma Strategy Editor for Asia-Pacific Region pharmaceutical intelligence editor on NovaPharmaNews, with 18 published articles covering NMPA regulatory actions, clinical development, and market-moving news. Kenji Watanabe leads APAC market coverage on portfolio strategy, launch prioritization, and cross-country commercialization. His 16 years in pharma strategy include advisory work for both multinational and regional specialty players.
About Kenji Watanabe
Kenji Watanabe leads APAC market coverage on portfolio strategy, launch prioritization, and cross-country commercialization. His 16 years in pharma strategy include advisory work for both multinational and regional specialty players.
Coverage focus
Topics and beats Kenji covers across Asia-Pacific Region.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Kenji Watanabe
Ascidian Therapeutics Completes ACDN-01 Dose Escalation in STELLAR Phase 1/2 Trial for Stargardt Disease
Ascidian Therapeutics completes adult dose escalation for ACDN-01 in Stargardt disease Phase 1/2 STELLAR trial, expands to pediatric patients.
UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases
UCB's $2.2B acquisition of Candid Therapeutics brings novel T-cell engager technology for autoimmune diseases, marking major expansion beyond oncology applications.
FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant
The FDA has granted approval for Pfizer and Arvinas' novel breast cancer drug, vepdegestrant. This marks a significant new treatment option for patients with advanced or metastatic HR-positive, HER2-negative breast cancer who have exhausted prior endocrine therapies.
NAMSA and Lexitas Form Strategic Partnership for Comprehensive Ophthalmic Medical Device Development Services
NAMSA partners with Lexitas Pharma Services to offer end-to-end ophthalmic medical device development, creating single-source solution for sponsors.
Taimei Technology Debuts AI-Powered Clinical Trial Platform at BioKorea 2026
Taimei Technology showcases AI-driven drug development platform at BioKorea 2026, planning Korea market entry with advanced clinical research solutions.
NMPA Priority Review Pathway: Accelerating Innovative Drug Approvals in China
The NMPA Priority Review Pathway accelerates the approval of innovative drugs in China, significantly benefiting patients with critical health needs.
Bispecific Antibody Approvals in EU: Teclistamab & Elranatamab Review
This article reviews the recent EU approvals of teclistamab and elranatamab, highlighting their significance in treating multiple myeloma.
Citius Oncology Ships First LYMPHIR International Order to Europe, Expanding Global Cancer Treatment Access
Citius Oncology ships first international LYMPHIR order to Europe through regional distribution partners, marking major milestone in global expansion.
COFEPRIS Guidelines Oncology: What You Need to Know About RWE Framework
Learn about COFEPRIS guidelines for oncology and the Real-World Evidence (RWE) framework essential for advancing cancer therapies.
ANVISA Regulatory Changes Brazil: Impact on Oncology & Infectious Disease Trials
This article examines the recent ANVISA regulatory changes in Brazil and their significant implications for oncology and infectious disease clinical trials.
ANVISA Priority Review Program: Clinical Trial Approval Timelines for Strategic Diseases
The ANVISA Priority Review Program accelerates clinical trial approvals for critical diseases, enhancing patient access to innovative therapies.
Arcera Life Sciences Partners with Fosun Pharma for Neurodegenerative Disease R&D Collaboration
Arcera Life Sciences and Fosun Pharma establish strategic framework for neurodegenerative disease research, licensing, and technology development.
SAHPRA Approval Trastuzumab Deruxtecan: What You Need to Know
SAHPRA has approved Trastuzumab Deruxtecan, a groundbreaking therapy for HER2-positive breast cancer, offering new hope for patients.
Akso Health Group Launches Brain-Computer Interface R&D Program Targeting Neurotechnology Market
Akso Health Group (NASDAQ: AHG) announces entry into brain-computer interface development, establishing R&D infrastructure for next-generation neurotechnology solutions.
IMG Pharma Acquires Matsumoto Pharmaceutical in Strategic Japanese Market Expansion Deal
IMG Pharmaceutical announces definitive agreement to acquire Matsumoto Pharmaceutical, expanding its presence in Japan's pharmaceutical manufacturing market.
CatalYm Doses First Patient in Phase 2/3 Trial of Visugromab for Cancer Cachexia
CatalYm begins Phase 2/3 VINCIT trial of visugromab, an anti-GDF-15 antibody targeting cancer cachexia in 518 patients with advanced cancers worldwide.
FDA Breakthrough Therapy Designation: Impact on Rare Disease Investment & Innovation
The FDA Breakthrough Therapy Designation accelerates drug development for rare diseases, enhancing investment and innovation in treatments like DMD.
Kelun-Biotech's Sacituzumab Tirumotecan and Two Other Cancer Drugs Selected for ASCO 2026 Oral Presentations
Kelun-Biotech announces three clinical studies selected for oral presentations at ASCO 2026, including TROP2 ADC sacituzumab tirumotecan results.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.